^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CUE-102

    i
    Other names: CUE-102, CUE 102, LR19129
    Associations

    News

    Trials
    Company:
    Cue Biopharma, LG Chem
    Drug class:
    IL-2 stimulant
    Related drugs:
    Associations

    News

    Trials
    over1year
    A phase 1, open-label, dose escalation and expansion study of CUE-102 monotherapy in HLA-A*0201 positive patients with WT1-positive recurrent/metastatic cancers (SITC 2022)
    Patients with colorectal and cisplatin-sensitive ovarian cancer must have documented disease progression to 2 prior systemic treatment regimens (CUE-102 will be ≥ 3rd line therapy); patients with Gastric/GEJ, pancreatic and cisplatin-resistant ovarian cancer must have documented disease progression to 1 prior systemic treatment regimens (CUE-102 will be ≥ 2nd line therapy). Results Trial is currently open and enrolling as of June 14, 2022.
    Clinical • P1 data
    |
    CD8 (cluster of differentiation 8) • WT1 (WT1 Transcription Factor) • IL2 (Interleukin 2)
    |
    HLA-A*02:01 • WT1 expression • WT1 positive
    |
    cisplatin • CUE-102
    almost2years
    A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers (clinicaltrials.gov)
    P1, N=52, Recruiting, Cue Biopharma | Not yet recruiting --> Recruiting
    Enrollment open
    |
    WT1 (WT1 Transcription Factor) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    WT1 expression • WT1 positive
    |
    CUE-102
    2years
    A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers (clinicaltrials.gov)
    P1, N=52, Not yet recruiting, Cue Biopharma
    New P1 trial
    |
    WT1 (WT1 Transcription Factor) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    WT1 expression • WT1 positive
    |
    CUE-102